Release date: 2018-03-22
Today, the US FDA announced the approval of Seattle Genetics' antibody conjugate Adcetris (brentuximab vedotin) to expand indications and use it in combination with chemotherapy to treat patients with stage III or IV classic Hodgkin's lymphoma.
Lymphoma is a cancer that develops in the lymphatic system and is mainly divided into Hodgkin's lymphoma and non-Hodgkin's lymphoma. Most Hodgkin's lymphoma patients are classified as "classic", and there are large abnormal lymphocytes in the lymph nodes - Reed-Sternberg cells. These patients often achieve long-term relief as long as the intervention is early enough.
Adcetris, which was approved today, is such a new drug that is expected to bring the gospel to lymphoma patients. As an antibody drug conjugate, it is composed of an antibody against a CD30 antigen, brentuximab, and an anti-mitotic drug, monomethyl astatin, E (MMAE). CD30 protein is a known molecular marker of classical Hodgkin's lymphoma, and MMAE is effective in inhibiting cell mitosis by inhibiting the polymerization of tubulin, which is separated by the proprietary protease of Seattle Genetics. The coupling is composed of coupling. Adcetris is stable in the blood circulation. When it is swallowed and internalized by CD30+ tumor cells, it releases MMAE, which leads to cell death.
In a clinical trial, the potential of Adcetris for the treatment of classic Hodgkin's lymphoma was validated—the researchers recruited 1,334 treated patients who had received an average of six 28-day cycles. Subsequently, they were divided into two groups, one receiving Adcetris and chemotherapy (AVD) and the other receiving chemotherapy (ABVD). Studies have shown that patients who receive combination therapy have a 23% lower risk of disease progression, death, or the need to start new treatment than patients who receive chemotherapy alone. In combination with G-CSF, a growth factor that promotes the growth of bone marrow leukocytes, the combination of Adcetris and chemotherapy is recommended by the FDA for first-line treatment of stage III or IV classic Hodgkin's lymphoma. In response to this indication, Adcetris has also been awarded the criteria for breakthrough therapy recognition and priority review.
It is worth mentioning that this is the fifth FDA approval of Adcetris. Previously, it was approved for the treatment of relapsed classic Hodgkin's lymphoma, a classic Hodgkin's lymphoma with high-risk recurrence or progression after stem cell transplantation, and systemic anaplastic large cell lymphocytes that have undergone other therapies but are ineffective. Tumor, as well as primary anaplastic large cell lymphoma of any other therapy.
"Today's approval represents an important advancement in advanced Hodgkin's lymphoma for more than 40 years," said Dr. Richard Pazdur, Director of the Center for Excellence in Cancer and Executive Director of the Department of Hematology and Oncology Products at the FDA Center: "This approval demonstrates the FDA. Commitment to bring new treatments to patients."
Reference materials:
[1] FDA expands approval of Adcetris for first-line treatment of Stage III or IV classical Hodgkin lymphoma in combination with chemotherapy
[2] FDA hands Seattle Genetics its 5th OK for Adcetris. But can they actually sell it for frontline Hodgkin lymphoma?
Source: WuXi PharmaTech
An organic compound formed by dehydration of amino acids, containing carboxyl and amino groups, and being amphoteric. Also known as "peptide".
Two, one of the amide. It consists of two or more amino acids joined by the amino group of one amino acid to the carboxyl group of the other. An amino acid cannot be called a peptide, nor can a peptide be synthesized, but must be a compound of two or more amino acids linked by a peptide bond. Compounds where two amino acids are linked by a peptide bond are called dipeptides; A compound with three amino acids linked by peptide bonds is called a tripeptide, and so on, a compound with thirty-four amino acids linked by peptide bonds is called a thirty-four peptide.
A peptide is a chain of polymers of amino acids
A peptide is a chain of polymers of amino acids
Three, is related to the biological body of a variety of cell functions of biological active substances. Hundreds of peptides have been found in living organisms, which are essential participants in the body's complex physiological activities. All cells can synthesize peptides and their functional activities are regulated by peptides. It involves hormones, nerves, cell growth and reproductive fields, and its importance lies in the regulation of various systems, organs and cells in the body. The physiological and pharmacological effects of enzymatic polypeptides are mainly to activate related enzymes in vivo, promote the permeability of intermediate metabolic membrane, or affect specific protein synthesis by controlling DNA transcription or translation, and eventually produce specific physiological effects or play their pharmacological effects. Peptide is better than amino acid, one is faster than amino acid absorption; Second, it is absorbed by the body in a complete form; Third, active absorption (amino acids are passive absorption); Fourth, low consumption, compared with amino acids, peptide absorption has the characteristics of low consumption or no energy consumption, peptide absorption through the duodenum, directly into the blood circulation, their own energy nutrition transported to various parts of the human body; Fifth, peptide absorption is less than amino acid, with the characteristics of unsaturated; Sixth, there are only 20 kinds of amino acids, with countable functions, while peptides take amino acids as substrates, which can be synthesized into hundreds of thousands of kinds.
It is mainly divided into medical polypeptide drugs, peptide antibiotics, vaccines, antimicrobial peptides for agricultural use, small peptides for feed, cosmetics for daily use, soybean polypeptides for food, corn polypeptides, yeast polypeptides and sea cucumber peptides.
From the functional point of view, can be divided into antihypertensive peptide, antioxidant peptide, cholesterol lowering peptide, opioid active peptide, high F value oligopeptide, food strong taste peptide and so on.
Active peptide, and nutrition, hormone, enzyme inhibition, regulation of immunity, antibacterial, antiviral, antioxidant has a very close relationship. Polypeptides are generally divided into: polypeptide drugs and polypeptide health products. Traditional peptide drugs are mainly peptide hormones. The development of peptide drugs has been developed into various fields of disease prevention and treatment, especially in the following fields. [2]
Antitumor polypeptide
Tumorigenesis is the result of many factors, but ultimately all involve the regulation of oncogene expression. In 2013, many tumor-related genes and regulatory factors have been discovered. Screening peptides specifically bound to these genes and regulatory factors has become a new hot spot in the search for anticancer drugs. For example, somatostatin has been used to treat endocrine tumors of the digestive system; American scholars found a hexapeptide can significantly inhibit adenocarcinoma in vivo; Swiss scientists have discovered an octapeptide that induces apoptosis in tumor cells. [2]
Antiviral polypeptide
By binding to specific receptors on host cells, viruses adsorb cells and rely on their own specific proteases for protein processing and nucleic acid replication. Therefore, peptides binding to host cell receptors or active sites such as viral proteases can be selected from the peptide library for antiviral therapy. In 2013, many small peptides with antiviral properties have been screened from peptide banks in Canada, Italy and other countries, and some small peptides have entered the stage of clinical trials. In June 2004, the Chinese Academy of Sciences institute of Microbiology came out of the news, which was undertaken by the Chinese Academy of Sciences known
buy peptides,peptides benefits,peptides bpc 157,peptides buy,peptides cjc 1295
Shaanxi YXchuang Biotechnology Co., Ltd , https://www.peptidenootropic.com